Loes H C Nissen1, Marieke Pierik, Lauranne A A P Derikx, Elke de Jong, Wietske Kievit, Tim R A van den Heuvel, Alexander R van Rosendael, Elsemieke I Plasmeijer, Pieter Dewint, Rob H A Verhoeven, Lucy I H Overbeek, Iris D Nagtegaal, Frank Hoentjen, Andrea E van der Meulen-de Jong. 1. *Department of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Radboud University Medical Center, Nijmegen, the Netherlands; †Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, the Netherlands; ‡Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands; §Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; ‖Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; ¶Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands; **Department of Gastroenterology and Hepatology, Maasstad Ziekenhuis, Rotterdam, the Netherlands; ††Department of Gastroenterology and Hepatology, Maria-Middelares Ziekenhuis, Gent, Belgium; ‡‡Netherlands Cancer Registry/Netherlands Comprehensive Cancer Organization, Eindhoven, the Netherlands; §§Stichting PALGA, Houten, the Netherlands; and ‖‖Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
Abstract
BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk to develop malignant melanoma and this risk may increase with use of anti-tumor necrosis factor (TNF) therapy. Impaired survival of immunosuppressed melanoma patients is reported in transplant and rheumatology patients. This study aims to (1) identify risk factors for melanoma development in patients with IBD, (2) compare clinical characteristics of melanoma in patients with IBD to the general population, and (3) assess the influence of immunosuppressive medication on survival. METHODS: We retrospectively searched the Dutch Pathology Database to identify all Dutch patients with IBD with cutaneous melanoma between January 1991 and December 2011. We then performed 2 case-control studies. To identify risk factors for melanoma development in IBD, we compared patients with IBD with melanoma to the general IBD population. To compare outcome and survival after melanoma diagnosis, we compared cases with non-IBD melanoma patients. RESULTS: We included 304 patients with IBD with melanoma, 1800 IBD controls, and 8177 melanoma controls. IBD cases had more extensive IBD (ulcerative colitis: pancolitis: cases 44.5% versus IBD controls without melanoma 28.1%; P < 0.01; Crohn's disease: ileal and colonic disease: cases 57.9% versus controls 48.9%; P = 0.02). Despite a lower Nodes (N)-stage in patients with IBD (N1+ 8.3% versus 18.2%; P < 0.01) with comparable Tumor (T) and Metastasis (M) stages, survival was similar between groups, regardless of immunosuppressive or anti-TNF therapy. CONCLUSIONS: This study showed that IBD extent is a risk factor for melanoma development. Despite the lower N-stage in patients with IBD, we could not confirm impaired survival after melanoma in patients with IBD, regardless of anti-TNF and/or thiopurine use.
BACKGROUND:Patients with inflammatory bowel disease (IBD) are at increased risk to develop malignant melanoma and this risk may increase with use of anti-tumor necrosis factor (TNF) therapy. Impaired survival of immunosuppressed melanomapatients is reported in transplant and rheumatologypatients. This study aims to (1) identify risk factors for melanoma development in patients with IBD, (2) compare clinical characteristics of melanoma in patients with IBD to the general population, and (3) assess the influence of immunosuppressive medication on survival. METHODS: We retrospectively searched the Dutch Pathology Database to identify all Dutch patients with IBD with cutaneous melanoma between January 1991 and December 2011. We then performed 2 case-control studies. To identify risk factors for melanoma development in IBD, we compared patients with IBD with melanoma to the general IBD population. To compare outcome and survival after melanoma diagnosis, we compared cases with non-IBD melanomapatients. RESULTS: We included 304 patients with IBD with melanoma, 1800 IBD controls, and 8177 melanoma controls. IBD cases had more extensive IBD (ulcerative colitis: pancolitis: cases 44.5% versus IBD controls without melanoma 28.1%; P < 0.01; Crohn's disease: ileal and colonic disease: cases 57.9% versus controls 48.9%; P = 0.02). Despite a lower Nodes (N)-stage in patients with IBD (N1+ 8.3% versus 18.2%; P < 0.01) with comparable Tumor (T) and Metastasis (M) stages, survival was similar between groups, regardless of immunosuppressive or anti-TNF therapy. CONCLUSIONS: This study showed that IBD extent is a risk factor for melanoma development. Despite the lower N-stage in patients with IBD, we could not confirm impaired survival after melanoma in patients with IBD, regardless of anti-TNF and/or thiopurine use.
Authors: Steffi E M van de Ven; Lauranne A A P Derikx; Iris D Nagtegaal; Carla M van Herpen; Robert P Takes; Willem J G Melchers; Marieke Pierik; Tim van den Heuvel; Rob H A Verhoeven; Frank Hoentjen; L H C Nissen Journal: Inflamm Bowel Dis Date: 2020-06-18 Impact factor: 5.325